DOI: https://doi.org/10.22141/2224-1485.2.58.2018.131061

Arterial hypertension and diabetes mellitus: questions of optimizing the control of arterial pressure

S.M. Koval, I.O. Snihurska, M.Yu. Penkova, O.M. Lytvynova, V.V. Bozhko, K.O. Yushko

Abstract


An overview of literature data is presented on the treatment of arterial hypertension in diabetic patients. Modern approaches to the drug treatment of arterial hypertension in this category of patients are considered. The detailed characteristics of the main antihypertensive drugs that are recommended for adequate control of arterial pressure in patients with diabetes mellitus are
given.


Keywords


arterial hypertension; diabetes mellitus; target blood pressure levels; antihypertensive drugs; review

References


Cleary P.A., Orchard T.J., Genuth S. et al. The effectof intensiveglycemic treatment on coronaryartery calcificationintype 1diabeticparticipants ofthe Diabetes Control and Complications Trial // Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Diabetes. 2006; 55: 3556-3565.

Soedamah-Muthu S.S., Colhoun H.M., Abrahamian H. et al. Trends in hypertension management in Type I diabetes across Europe, 1989/1990–1997/1999 // Diabetologia. 2002; 45: 1362-1371.

Haffner S.M., Lehto S., Ronnemaa T. et al. Mortality from coronaryheart disease in subjects with type 2 diabetes and in nondiabetic subjects withand without prior myocardial infarction // N. Engl. J. Med. 1998; 339: 229-234.

Mogensen C.E. Newtreatment guidelines for a patient with diabetes and hypertension // J. Hypertens. Suppl. 2003; 21: S25-30.

Redon J., Cifkova R., Laurent S. et al. Mechanisms of hypertension in the cardiometabolic syndrome // J. Hypertens. 2009; 27: 441-451.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of microvascular and microvascular complications in type 2 diabetes: UKPDS 38 // BMJ. 1998; 317: 703-713.

Preiss D., Sattar N., McMurray J.J. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design // Am. Heart J. 2011; 161(1): 210-219.

Barkoudah E., Skali H., Uno H. et al. Mortality rates in trials of subjects with type 2 diabetes // J. Am. Heart Assoc. 2012; 1(1): 8-15.

Schrier R.W., Estacio R.O., Mehler P.S., Hiatt W.R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial // Nat. Clin. Pract. Nephrol. 2007; 3: 428-438.

Sundström J., Sheikhi R., Ostgren C.J. et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients // J. Hypertens. 2013; 31: 1603-10.

ESH/ESC Guidelines for management of arterial hypertension // J. of Hypertension. 2013; 31: 1281-1357.

Hansson L., Zanchetti A., Carruthers S. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. 2000; 352: 1755-1762.

Cederholm J., Gudbjornsdottir S., Eliasson B., Zetheli-us B., Eeg-Olofsson K., Nilsson P.M. Blood pressure and risk of cardiovascular disease in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP-II) // J. Hypertens. 2012; 30: 2020-2030.

Brunström M., Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses // BMJ. 2016; 352. doi: https://doi.org/10.1136/bmj.i717.

Wright J.T. Jr, Williamson J.D., Whelton P.K. et al. SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control // N. Engl. J. Med. 2015; 373: 2103-16.

Zhao W., Katzmarzyk P.T., Horswell R. et al. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients // Diabetes Care. 2013; 36: 3287-96.

American Diabetes Association. Risk Managment Standarts of Medical Care in Diabetes: Cardiovascular Disease and Risk Management // Diabetes Care. 2016; 39 (Suppl. I): 60-71.

Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування / За ред. В.М. Коваленка, М.І. Лутая, Ю.М. Сіренка, О.С. Сичова. — К.: МОРІОН, 2016. — 192 с.

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD // European Heart Journal. 2013; 34: 3035-3087.

Whelton P.K. et al. High Blood Pressure Clinical Practice Guideline: Executive Summary. A Report of the American College of Cardiology // American Heart Assiciation Task Force on Clinical Practic Guidelines. 2017; 401.

Emdin C.A., Rahimi K., Neal B. et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis // JAMA. 2015; 313: 603-15.

Nilsson P.M. Hypertension in diabetes mellitue //

Manual of hypertension of the European Society of Hypertension / Ed. by G. Mancia, G. Grassi and J. Redon. 2014; 384-393.

Bangalore S., Fakheri R., Toklu B., Messerli F.H. Diabetes mellitusas a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials [published correction appears in BMJ 2016;352:i1 525] // BMJ. 2016; 352: i438.

Palmer S.C., Mavridis D., Navarese E. et al. Comparative efficacy and safety of blood pressure lowering agents in adults with diabetes and kidney disease: a network meta-analysis // Lancet. 2015; 385: 2047-2056.

Remonti L.R., Dias S., Leitгo C.B. et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetesNetwork meta-analysis of randomized trials // J. Diabetes Complications. 2016; 30: 1192-1200.

Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses // J. Hypertens. 2015; 33: 1321-41.

Whelton P.K., Barzilay J., Cushman W.C. et al. ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. 2005; 165: 1401-1409.

Catalá-López F., Macías Saint-Gerons D., González-Bermejo D. et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses // PLoS Med. 2016 Mar 8; 13(3): e1001971. doi: 10.1371/journal.pmed.1001971.

Estacio R.O., Jeffers B.W., Hiatt W.R. et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension // N. Engl. J. Med. 1998; 338: 645-652.

Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. 2000; 355:

-259.

Julius S., Kjeldsen S.E., Weber M. et al. VALUE trial group. Outcomes in hypertensive patientes at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomised trial // Lancet. 2004; 363: 2022-2031.

Lindholm L.H., Ibsen H., Dahlof F. et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Enpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. 2002; 359: 1004-1010.

Patel A., ADVANCE Collaborative Group, MacMa-

hon S. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. 2007; 370: 829-840.

Fried L.F., Emanuele N., Zhang J.H. et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy // N. Engl. J. Med. 2013; 369: 1892-1903.

ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. 2008; 358: 1547-1559.

Parving H.H., Brenner B.M., McMurray J.J.V. et al. Cardiorenal end 4129 points in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. 2012; 367: 2204-2213.

Mancia G., Schumacher H., Redon J. et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) // Circulation. 2011; 124: 1727-1736.

Agabiti-Rosei E., Manolis A., Zava D., Omboni S. Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non-diabetic Essential Hypertensive Patients // Adv. Ther. 2014; 31: 217-233.

Dahlof F., Sever P., Poulter N.R. et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as requered versus atenolol adding bendroflumethiazide as requered, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentere randomised controled trial // Lancet. 2005; 366: 895-906.

Lindholm L.H., Hansson L., Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old patients with hypertension-2. STOP Hypertension Study Group //J. Hypertens. 2000; 18: 1671-1675.

Brenner B.M., Cooper M.E., de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. 2001; 345: 861-869.

Lewis E.J., Hansicker L./G., Clarke W.R. et al. Renoprotective effect on the angiotensin-receptor antagonist irbesartan in patientes with nephropathy due to type 2 diabetes // N. Engl. J. Med. 2001; 345: 851-860.

Menne J., Ritz E., Ruilope L.M. et al. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow-Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation // J. Am. Heart. Assoc. 2014; 3: 1-13.

Вдовиченко В.І., Кульчицький В.В. Гіпертонічна хвороба в поєднанні із цукровим діабетом 2 типу: суперечливість поглядів на тактику ведення // Український терапевтичний журнал. 2015; 1: 63-68.

Маньковский Б.Н. Лечение артериальной гипертензии у больных сахарным диабетом // Ліки України. 2009; 2: 4-8.

Kiya Y.Clinical and Pharmacotherapeutic Relevance of the Double-Chain Domain of the Angiotensin II Type 1, Receptor Blocker Olmesartan // Clin. Exp. Hypertens. 2010 January; 32(2): 129-136.

Daikuhara H., Fukunaga K., Ohshima T. Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study // Drug. Design, Development and Therapy. 2014; 8: 219-226.

Ono T., Sanai T., MiyaharaY., Noda R. Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy // Current Therapeutic Research. 2013; 74: 62-67.

Sezai A., Osaka S., Yaoita H. et al. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study) // Ann. Thorac. Cardiovasc. Surg. 2016; 22: 161-167.

Ruilope L. Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes // J. Clin. Hypertens. (Greenwich). 2015: 1-8.

Ushijima K., Nakashima H., Shiga T. et al. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatmentat morning // Journal of Pharmacological Sciences. 2015; 127: 62-68.

Савустьяненко А.В. Органопротекторные свойства индапамида предотвращают формирование неблагоприятных клинических исходов // Артериальная гипертензия. 2011; 4(18): 89-94.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, Journal of the American College of Cardiology (2017), doi: 10.1016/j.jacc.2017.11.006.

Амосова К.М., Руденко Ю.В. Уніфікований алгоритм антигіпертензивної терапії та контроль домашнього артеріального тиску у хворих з ймовірно резистентною артеріальною гіпертензією в амбулаторній практиці // Укр. кардіол. журн. 2015; 4: 25-33.

Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study // J. Hypertens. 2000; 18(10): 1465-1475.

Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. 2005; 165: 1410-1419.

Agabiti-Rosei E., Trimarco B., Muiesan M.L., Reid J., Salvetti A., Tang R., Hennig M., Baurecht H., Parati G., Mancia G., Zanchetti A. ELSA Echocardiographic Substudy Group. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA) // J. Hypertens. 2005; 23: 1091-1098.

Devereux R.B., Palmieri V., Sharpe N., De Quattro V., Bella J.N., de Simone G., Walker J.F., Hahn R.T., Dahlof B. Effects of once-daily angiotensinconverting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial // Circulation. 2001; 104: 1248-1254.

Messerli F.H. Calcium antagonists in hypertension: from hemodynamics to outcomes // Amer. J. Hypertens. 2002; 15: 945-975.

Terpstra W.F., May J.F., Smit A.J. et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial // J. Hypertens. 2001; 19: 303-309.

Zanchetti A., Ruilope L.M., Cuspidi C., Macca G., Verschuren J., Kerselaers W. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study //

J. Hypertens. 2001; 19(Suppl 2): S92. (abstract).

Agrawal R., Marx A., Haller Y. Efficiency and safety of lercanipine versus hydrochlorothiazide as add on to enalapril in diabetic population with uncontrolled hypertension // J. Hypertens. 2006; 24(1): 185-192.

McClellan K.J., Jarvis B. Lercanipine. A review of its use in hypertension // Drugs. 2000; 60(5): 1123-1140.

Peng M.I., Jiang X.J., Dong H. et al. lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention // Curr. Med. Res. Opin. 2015; 31(1): 177-82.

Qrtiz M., Calcino G., Solvay Pharmaceuticals et al.

Inferred mortality differences between dihydropyridine antihypertensives // Hypertension. 2009; 53: 1116.

Romito R., Pancini M., Francesco P.F. et al. Comparative effect of Lercanidipine Felodipine and Nifedipine GITS on blood pressure and heart rate in patient with mild and moderate arterial hypertension. The Lercanidine in adults (LEAD) study // JCN. 2003; 4: 5: 249-253.

Zancetti A., Bond G., Henning M et al. Emerging data on calcium channel blockers: the COHORT study // Clin. Cardiol. 2003; 26: Supple 2, II: 17-20.

Візір В.А., Волошина І.М. Лерканідипін: нові аспекти патогенетичного лікування у хворих на гіпертонічну хворобу // Артериальная гипертензи. 2013; 3(29): 7-10.

Лукина Ю.В., Марцевич С.Ю. Позиции антагониста кальция лерканидипина по данным доказательной медицины // Рациональная фармакотерапия в кардиологии. 2010; 6(4): 558-564.

Burnier M., Pruijm M., Wuerzner G. Treatment of essential hypertension with calcium channel blockers: what is the place the lercanidipine // Expert. Opinion. Drug. Metabol. Toxicol. 2009; 5(8): 981-987.

Viviani G.L. Lercanidipine in type II diabetic patients with mild moderate arterial hypertension // J. Cardiovasc. Pharmacol. 2002; 40(1): 133-9.

Borghi C., Desideri G., Taddei S., Trimarco B. 3 dimensions in hypertension management // SINERGIE. 2017; 62.

Wiysonge C.S., Bradley H.A., Volmink J. et al. Beta-blockers for hypertension // Cochrane Database Syst. Rev. 2017 Jan 20; 1: CD002003. doi: 10.1002/14651858.CD002003.pub5.

Сиренко Ю.Н., Рековец О.Л., Кушнир С.Н. и др. Сравнительная эффективность небиволола и бисопролола в плане влияния на центральное артериальное давление и упруго-эластические свойства артерий у пациентов с мягкой и умеренной артериальной гипертензией // Артериальная гипертензия. 2013; 1(27): 9-18.

Bakris G.L., Fonseca V., Katholi R.E. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // JAMA. 2004; 292: 2227-2236.

Celik T., Iyisoy A., Kursaklioglu H. et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients // J. Hypertens. 2006; 24: 591-596.

Stears A.J., Woods S.H., Watts M.M. et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension // Hypertension. 2012; 59: 934-942.

Рудык Ю.С. Моксонидин в современном лечении артериальной гипертензии // Раціональна фармакотерапія. 2017; 3(44): 5-12.

Срожидинова Н.З., Тухтаев А.А. Эффективность моксонидина в лечении больных артериальной гипертензией с метаболическим синдромом // Артериальная гипертензия. 2013; 3(29): 42-47.

Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом (результаты исследования ALMAZ) // Consilium Medicum. Прил. Системн. гиперт. 2006; 2: 14-18.

Чазова И.Е., Мычка В.Б., Ратова Л.Г. (от лица исследовательской группы). Место агонистов имидазолиновых рецепторов в лечении артериальной гипертензии: результаты исследования MERSY в России // Системные гипертензии. 2009; 3: 22-24.

Bobrie G., Frank M., Azizi M. et al. Sequential nephron blockade vs. sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study // J. Hypertens. 2012; 30: 1656-1664.

Zannad F., McMurray J.J., Krum H. et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms // N. Engl. J. Med. 2011; 364: 11-21.

O’Brien E., Barton J., Nussberger J. et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker // Hypertension. 2007; 49: 276-284.

Littlejohn T.W. 3rd, Trenkwalder P., Hollanders G. et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension // Curr. Med. Res. Opin. 2009; 25: 951-959.

Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N. Engl. J. Med. 2008; 358: 2433-2446.

Gheorghiade M., Bohm M., Greene S.J. et al. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. The ASTRONAUT Randomized Trial // JAMA. 2013; 309: 1125-1135.

Seed A., Gardner R., McMurray J. et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure // Eurj. Heart. Fail. 2007; 9: 1120-1127.

Свіщенко Є.П. Вплив комбінації лозартану та амлодипіну на добовий профіль артеріального тиску, рівень церебрального кровотоку та функціональний стан нирок у хворих на гіпертонічну хворобу / Є.П. Свіщенко, В.Б. Безродний, О.А. Яринкіна // Укр. мед. вісник. 2013; 9: 73-77.

Сіренко Ю.М., Радченко Г.Д., Поліщук С.А. Відкрите рандомізоване порівняльне паралельне клінічне дослідження антигіпертензивної ефективності генеричного та брендового комбінованих препаратів ірбесартану та гідрохлортіазиду при гіпертонічній хворобі ІІ–ІІІ ступеня // Артериальная гипертензия. 2015; 2(40): 70-81.

Tatti P., Pahor M., Byington R.P. et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM // Diabetes Care. 1998; 21: 597-603.

Jamerson K., Weber M.A., Bakris G.L. et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. 2008; 359: 2417-2428.

Weber M.A., Bakris G.L., Jamerson K. et al. ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes // J. Am. Coll. Cardiol. 2010; 56: 77-85.

Hermida R.C., Ayala D.E., Mojón A., Fernández J.R. Influence of time of day of blood pressurelowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes // Diabetes Care. 2011; 34: 1270-1276.

Zhao P., Xu P., Wan C., Wang Z. Evening versus morning dosing regimen drug therapy for hypertension // Cochrane Database Syst. Rev. 2011; 10: CD004184.




Copyright (c) 2018 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта